The ban will not prevent life insurers from using family medical history in underwriting. It will simply prohibit them from using adverse genetic tests to obtain much of the information they already have through very intrusive questions in the existing underwriting process. …
The confusing public debate might be more of a risk to confidence in genetic testing
February 16, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
CSL unveils US expansion, cementing its position as a global biopharma leader
November 19, 2025 - - Latest News -
Cleo Diagnostics appoints U.S. oncologist as first key opinion leader
November 19, 2025 - - Australian Biotech -
IDT Australia resets strategy as advanced therapies drive new phase of growth
November 19, 2025 - - BioPharma -
Dimerix Phase 3 kidney trial clears seventh safety review
November 19, 2025 - - Australian Biotech -
Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas
November 19, 2025 - - Australian Biotech -
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech -
Is this disconnect so entrenched we can no longer recognise the presence of a problem?
November 19, 2025 - - Latest News